We are a biotechnology company that is dedicated to developing treatments for medical conditions that have the potential to change people’s lives. We see each clinical trial as a key milestone on this journey.
Patients are our North Star. We aim to develop innovative treatments focused on the health outcomes that matter most to patients by understanding their unique needs, priorities and perspectives. And we can only do that by engaging with them in trust-based, long-lasting and mutually beneficial partnerships, as outlined by our Patient Partnership Charter.
Focusing on high unmet medical needs, we combine the most compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules, cell therapies, and biologics in oncology and immunology.
We are not constrained by the current situation. Our in-depth expertise means we can adapt and meet challenges as a unique opportunity.
We follow rigorous procedures and guidelines to ensure Galapagos is able to deliver to the highest standards and ethics for healthy volunteers and patients.
We aim to address patient needs through transformational innovation in oncology and immunology. We bring together the best science, technology and next-generation biological capabilities from inside and outside our company to accelerate our approach in small molecules, biologicals and cell therapy.
We are pioneering for patients, with patients.
We work with multiple drug modalities and combinations and apply deep medical condition expertise.
We combine internal and external innovation and partner with academia, biopharma’s and patient organizations.
Teamwork is key to accelerate innovation.
We have ongoing clinical trials in immunology and oncology in America (both in the United States and in South America) and in Europe (including in the United Kingdom).
If you are an investigator and interested in working with Galapagos, please contact us.